Second-Line Dasatinib and Nilotinib in Real-World Chronic Myeloid Leukemia
The following is a summary of “Second-line use of dasatinib and nilotinib in a real-world patient population with chronic phase chronic myeloid leukemia,” published in the March 2025 issue of Hematology by Toptas et ...
